ClinicalTrials.gg
CompletedNCT06219655Updated Jan 23, 2024

Extended Versus Limited Thoracoscopic Sympathectomy: Its Impact on Palmar and Plantar Hyperhidrosis

An interventional study of thoracoscopic sympathectomy in Hyperhidrosis Due to Autonomic Dysregulation (Disorder), sponsored by Mansoura University. Completed at 1 site in Egypt. Open to participants aged 6 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-23.

Sponsored by Mansoura University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 11 months after the study started (first participant enrolled Jan 2019, registered Jan 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
6 Years to 24 Years
Sex
All
01

Study summary

Conclusions: In the context of palmar and plantar hyperhidrosis, extended thoracoscopic sympathectomy seemed to be preferred over limited thoracoscopic sympathectomy due to better overall outcomes and minimal time for hospital stays and Compensatory hyperhidrosis.

Read the detailed description

ABSTRACT Objective: The aim was to carefully evaluate and compare the results of extended sympathectomy versus T3, T4, and T5 resection in cases of palmer, axillary, and planter hyperhidrosis as regards decreased sweating and recurrence rates.

Methods: This was a randomized controlled prospective trial conducted at the Department of Vascular Surgery Mansoura University Hospitals on a total of 120 patients with hyperhidrosis who were divided into two groups; group 1 who had undergone limited sympathectomy and group 2 who had undergone extended sympathectomy.

02

Conditions studied

  • Hyperhidrosis Due to Autonomic Dysregulation (Disorder)

Browse trials for

03

In context

Hyperhidrosis

111 studies on the registry are indexed under Hyperhidrosis; 10 are open to participants now.

This study's enrollment of 120 is above the median of 50 across 99 interventional studies indexed under Hyperhidrosis.

Browse Hyperhidrosis studies →

Lead sponsor

Mansoura University is the lead sponsor of 1,119 studies on the registry; 183 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of hyperhydrosis
  • Able to take drugs
  • Palmer and planter hyperhydrosis
  • Age from 6-24 years
  • Interfere with daily activities

Exclusion criteria

Exclusion Criteria:

  • Not fit for surgery
  • Thyroid disease
  • age less than 6 years
  • Chest or cardiac problems
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Extended symathectomy

    Procedure: thoracoscopic sympathectomy

  • Active comparator
    limited sympathectomy

    Procedure: thoracoscopic sympathectomy

Interventions

  • Procedurethoracoscopic sympathectomy

    sympathectomy

06

What researchers measure

Primary outcomes

  1. hyperhidrosis dryness of hands

    dryness of both hands and feet- difference in temperature hands and feet before and after-starch iodine test

    Time frame: from 2019-2023 over 4 years

  2. dryness of both feet

    dryness of both hands and feet- difference in temperature hands and feet before and after-starch iodine test

    Time frame: from 2019-2023 over 4 years

07

Study locations

1 site
  • Mansoura University
    Mansoura, 7650005, Egypt
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Mar 2022, 37 months.

Of 20 interventional studies with no phase under Hyperhidrosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 37. This study's 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2024
First posted
Jan 23, 2024
StartActual
Jan 18, 2019
Primary completionActual
Mar 5, 2022
CompletionActual
Jan 1, 2024
Last update
Jan 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06219655
Responsible party
Mohamed emad (Lecturer of vascular surgery, Mansoura University) — Principal investigator
First posted
Jan 23, 2024
Start date
Jan 18, 2019
Primary completion
Mar 5, 2022
Completion
Jan 1, 2024
Last update
Jan 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion